Ricci Jean-Ehrland
Université Côte d'Azur, INSERM, C3M, Nice, France; Équipe labellisée LIGUE Contre le Cancer, Nice, France.
Cell Rep. 2025 Jan 28;44(1):115206. doi: 10.1016/j.celrep.2024.115206. Epub 2025 Jan 10.
Metabolic reprogramming in both immune and cancer cells plays a crucial role in the antitumor immune response. Recent studies indicate that cancer metabolism not only sustains carcinogenesis and survival via altered signaling but also modulates immune cell function. Metabolic crosstalk within the tumor microenvironment results in nutrient competition and acidosis, thereby hindering immune cell functionality. Interestingly, immune cells also undergo metabolic reprogramming that enables their proliferation, differentiation, and effector functions. This review highlights the regulation of antitumor immune responses through metabolic reprogramming in cancer and immune cells and explores therapeutic strategies that target these metabolic pathways in cancer immunotherapy, including using chimeric antigen receptor (CAR)-T cells. We discuss innovative combinations of immunotherapy, cellular therapies, and metabolic interventions that could optimize the efficacy of existing treatment protocols.
免疫细胞和癌细胞中的代谢重编程在抗肿瘤免疫反应中起着至关重要的作用。最近的研究表明，癌症代谢不仅通过改变信号传导维持致癌作用和细胞存活，还调节免疫细胞功能。肿瘤微环境中的代谢串扰会导致营养物质竞争和酸中毒，从而阻碍免疫细胞功能。有趣的是，免疫细胞也会经历代谢重编程，以实现其增殖、分化和效应功能。本综述强调了通过癌症和免疫细胞中的代谢重编程来调节抗肿瘤免疫反应，并探讨了在癌症免疫治疗中针对这些代谢途径的治疗策略，包括使用嵌合抗原受体（CAR）-T细胞。我们讨论了免疫疗法、细胞疗法和代谢干预的创新组合，这些组合可以优化现有治疗方案的疗效。
